E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group
Pharmacology, Toxicology and Pharmaceutical Science
6
4%
Nursing and Health Professions
5
4%
Neuroscience
3
2%
Other
8
6%
Unknown
83
61%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2021.
All research outputs
#1,660,389
of 34,457,357 outputs
Outputs from Journal of Clinical Oncology
#4,651
of 32,547 outputs
Outputs of similar age
#30,980
of 467,107 outputs
Outputs of similar age from Journal of Clinical Oncology
#63
of 115 outputs
Altmetric has tracked 34,457,357 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,547 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.5. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 467,107 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 115 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
